# US 2019/0315841 A1 · Antibody-Based Molecules Specific for the Truncated ASP421 Epitope of Tau and Their Uses in the Diagnosis and Treatment of Tauopathy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315841 A1
- Document ID: US20190315841A1
- Status: Published application
- Kind: A1
- Application number: 15/750,975
- Filed: 2016-08-11
- Published: 2019-10-17
- Earliest claimed: 2015-08-13
- Assignees: New York University
- Applicants: New York University
- Inventors: Einar Sigurdsson
- Web page: https://patentgrep.com/patent/US20190315841A1

## CPC

- C07K 16/18: against material from animals or humans
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- G01N 33/532: Production of labelled immunochemicals
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G01N 2800/2821: Alzheimer
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to antibody-based molecules (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically and selectively binding to the truncated Asp421 epitope of Tau. Such antibody-based molecules are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis and/or treatment of Alzheimer's disease or other tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The antibody-based molecules of the present invention have particular utility as diagnostic markers for, Alzheimer's disease and related tauopathies and as pharmaceutical compositions for the treatment of such conditions.

## Claims

### Claim 1

An antibody-based molecule that is capable of immunospecifically binding to the Truncated Asp421 Epitope of Tau, wherein said epitope is present on a peptide having the sequence of Tau 407-421 (SEQ ID NO:7): HLSNVSSTGSIDMVD,
wherein:
(A) said aspartate residue of SEQ ID NO:7 is the C-terminal Tau residue of said polypeptide; and
(B) relative to said immunospecific binding, said antibody-based molecule exhibits substantially diminished binding to a polypeptide that contains additional Tau sequence residues C-terminal to said aspartate residue of SEQ ID NO:7.

### Claim 2 (depends on 1)

The antibody-based molecule of claim 1, wherein said molecule competes for binding with an antibody selected from the group consisting of:
Antibody 1G10D2 comprising: (i) a Variable Light Chain CDR1, CDR2, CDR3 respectively having the amino acid sequence of SEQ ID NOs:9, 10 and 11; and (ii) a Variable Heavy Chain CDR1, CDR2, CDR3 respectively having the amino acid sequence of SEQ ID NOs:13, 14 and 15;
Antibody 1G11A10 comprising: (i) a Variable Light Chain CDR1, CDR2, CDR3 respectively having the amino acid sequence of SEQ ID NOs:17, 18 and 19; and (ii) a Variable Heavy Chain CDR1, CDR2, CDR3 respectively having the amino acid sequence of SEQ ID NOs:21, 22 and 23;
Antibody 5B3C11(VL1) comprising: (i) a Variable Light Chain CDR1, CDR2, CDR3 respectively having the amino acid sequence of SEQ ID NOs:25, 26 and 27; and (ii) a Variable Heavy Chain CDR1, CDR2, CDR3 respectively having the amino acid sequence of SEQ ID NOs:33, 34 and 35;
Antibody 5B3C11(VL2) comprising: (i) a Variable Light Chain CDR1, CDR2, CDR3 respectively having the amino acid sequence of SEQ ID NOs:29, 30 and 31; and (ii) a Variable Heavy Chain CDR1, CDR2, CDR3 respectively having the amino acid sequence of SEQ ID NOs:33, 34 and 35; and
Antibody 5G2A3 comprising: (i) a Variable Light Chain CDR1, CDR2, CDR3 respectively having the amino acid sequence of SEQ ID NOs:37, 38 and 39; and (ii) a Variable Heavy Chain CDR1, CDR2, CDR3 respectively having the amino acid sequence of SEQ ID NOs:41, 42 and 43.

### Claim 3 (depends on 1)

The antibody-based molecule of claim 1, wherein said molecule comprises:
(a) (1) a Variable Light Chain CDR1, CDR2, CDR3 respectively having the amino acid sequence of SEQ ID NOs:9, 10 and 11; and
(2) a Variable Heavy Chain CDR1, CDR2, CDR3 respectively having the amino acid sequence of SEQ ID NOs:13, 14 and 15;
(b) (1) a Variable Light Chain CDR1, CDR2, CDR3 respectively having the amino acid sequence of SEQ ID NOs:17, 18 and 19; and
(2) a Variable Heavy Chain CDR1, CDR2, CDR3 respectively having the amino acid sequence of SEQ ID NOs:21, 22 and 23;
(c) (1) a Variable Light Chain CDR1, CDR2, CDR3 respectively having the amino acid sequence of SEQ ID NOs:25, 26 and 27; and
(2) a Variable Heavy Chain CDR1, CDR2, CDR3 respectively having the amino acid sequence of SEQ ID NOs:33, 34 and 35;
(d) (1) a Variable Light Chain CDR1, CDR2, CDR3 respectively having the amino acid sequence of SEQ ID NOs:29, 30 and 31; and
(2) a Variable Heavy Chain CDR1, CDR2, CDR3 respectively having the amino acid sequence of SEQ ID NOs:33, 34 and 35;
or
(e) (1) a Variable Light Chain CDR1, CDR2, CDR3 respectively having the amino acid sequence of SEQ ID NOs:37, 38 and 39; and
(2) a Variable Heavy Chain CDR1, CDR2, CDR3 respectively having the amino acid sequence of SEQ ID NOs:41, 42 and 43.

### Claim 4 (depends on 1)

The antibody-based molecule of claim 1, wherein said molecule comprises:
(a) a Variable Light Chain CDR1, CDR2, CDR3 respectively having the amino acid sequence of SEQ ID NOs:97, 98 and 99; and
(b) a Variable Heavy Chain CDR1, CDR2, CDR3 respectively having the amino acid sequence of SEQ ID NOs:100, 101 and 102.

### Claim 5 (depends on 1)

The antibody-based molecule of any of claim 1, wherein upon peripheral injection into a recipient, said molecule substantially co-localizes with a Tau aggregate.

### Claim 6 (depends on 1)

The antibody-based molecule of any of claim 1, wherein said molecule is an antibody, a diabody, an scFv, or comprises an epitope-binding fragment of an antibody, diabody or scFv.

### Claim 7 (depends on 6)

The antibody-based molecule of claim 6, wherein said molecule is an antibody.

### Claim 8 (depends on 6)

The antibody-based molecule of claim 6, wherein said molecule is a humanized antibody or comprises an epitope-binding fragment of a humanized antibody.

### Claim 9 (depends on 6)

The antibody-based molecule of claim 6, wherein said molecule is an scFv.

### Claim 10 (depends on 1)

The antibody-based molecule of any of claim 1, which is detectably labeled.

### Claim 11 (depends on 10)

The antibody-based molecule of claim 10, wherein said detectable label is a fluorescent label, a chemoluminescent label, a paramagnetic label, a radioisotopic label or an enzyme label.

### Claim 12 (depends on 10)

A method for detecting or measuring the presence or amount of truncated Tau protein in the brain, cerebrospinal fluid, blood, serum or plasma of a recipient subject, wherein said method comprises contacting said brain, cerebrospinal fluid, blood, serum or plasma of said subject with the antibody-based molecule of claim 10 and detecting or measuring binding between said truncated Tau protein and said antibody-based molecule.

### Claim 13 (depends on 12)

The method of claim 12, wherein said detection or measurement comprises in vivo or ex vivo imaging of said antibody-based molecule bound to said truncated Tau protein.

### Claim 14 (depends on 12)

The use method of claim 12, wherein said detection or measurement is for diagnosing Alzheimer's disease or another tauopathy of a subject.

### Claim 15 (depends on 1)

A pharmaceutical composition for the treatment of Alzheimer's disease or another tauopathy of a subject in need thereof, wherein said pharmaceutical composition comprises an effective amount of the antibody-based molecule of claim 1, and one or more carriers, diluents and/or stabilizers.

### Claim 16 (depends on 13)

The method of claim 13, wherein said detection or measurement is for the treatment of Alzheimer's disease or another tauopathy of said subject.

### Claim 17

(canceled)

### Claim 18 (depends on 14)

A kit for detecting or measuring the presence or amount of said truncated Tau protein in the brain of a subject, or for diagnosing Alzheimer's disease or another tauopathy in a subject, wherein said kit comprises the antibody-based molecule of claim 14.

### Claim 19 (depends on 14)

The method of claim 14, wherein said tauopathy is selected from the group comprising frontotemporal dementia, parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy, corticobasal degeneration, Pick's disease, progressive subcortical gliosis, tangle only dementia, diffuse neurofibrillary tangles with calcification, argyrophilic grain dementia, amyotrophic lateral sclerosis parkinsonism-dementia complex, dementia pugilistica, Down syndrome, Gerstmann-Straussler-Scheinker disease, Hallerworden-Spatz disease, inclusion body myositis, Creutzfeld-Jakob disease, multiple system atropy, Niemann-Pick disease type C, prion protein cerebral amyloid angiopathy, subacute sclerosing panencephalitis, myotonic dystrophy, non-guanamian motor neuron disease with neurofibrillary tangles, postencephalitic parkinsonism, acute traumatic brain injury and chronic traumatic encephalopathy.

### Claim 20 (depends on 15)

The pharmaceutical composition of claim 15, wherein said tauopathy is selected from the group comprising frontotemporal dementia, parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy, corticobasal degeneration, Pick's disease, progressive subcortical gliosis, tangle only dementia, diffuse neurofibrillary tangles with calcification, argyrophilic grain dementia, amyotrophic lateral sclerosis parkinsonism-dementia complex, dementia pugilistica, Down syndrome, Gerstmann-Straussler-Scheinker disease, Hallerworden-Spatz disease, inclusion body myositis, Creutzfeld-Jakob disease, multiple system atropy, Niemann-Pick disease type C, prion protein cerebral amyloid angiopathy, subacute sclerosing panencephalitis, myotonic dystrophy, non-guanamian motor neuron disease with neurofibrillary tangles, postencephalitic parkinsonism, acute traumatic brain injury and chronic traumatic encephalopathy.

### Claim 21 (depends on 16)

The method of claim 16, wherein said tauopathy is selected from the group comprising frontotemporal dementia, parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy, corticobasal degeneration, Pick's disease, progressive subcortical gliosis, tangle only dementia, diffuse neurofibrillary tangles with calcification, argyrophilic grain dementia, amyotrophic lateral sclerosis parkinsonism-dementia complex, dementia pugilistica, Down syndrome, Gerstmann-Straussler-Scheinker disease, Hallerworden-Spatz disease, inclusion body myositis, Creutzfeld-Jakob disease, multiple system atropy, Niemann-Pick disease type C, prion protein cerebral amyloid angiopathy, subacute sclerosing panencephalitis, myotonic dystrophy, non-guanamian motor neuron disease with neurofibrillary tangles, postencephalitic parkinsonism, acute traumatic brain injury and chronic traumatic encephalopathy.
